KORTUC Is Upgrading Radiotherapy From the Inside—And Giving Radiation-Resistant Cancer Patients a Second Chance
KORTUC is a clinical-stage oncology company addressing the failure of radiotherapy in about 10% of cancer patients due to hypoxic tumors. Their stabilized hydrogen peroxide radiosensitizer enhances radiation efficacy without requiring new machines or workflows. Proven in over 1,300 patients in Japan, KORTUC aims to improve patient outcomes globally.
